Unlock instant, AI-driven research and patent intelligence for your innovation.

Pharmaceutical composition for improving insulin resistance symptoms

A technology of insulin resistance and composition, which is applied in the directions of drug combination, pharmaceutical formula, and medical preparations containing active ingredients, etc., can solve the problems of unclarified medicinal parts and astragalus polysaccharides.

Pending Publication Date: 2022-07-05
BEIJING FRIENDSHIP HOSPITAL CAPITAL MEDICAL UNIV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Previous studies used large doses of metformin (500 mg / kg) and astragalus polysaccharide (1500 mg / kg) to treat aging type 2 diabetic mice. Mitochondria and endoplasmic reticulum have a protective effect and improve liver glucose and lipid metabolism in aging diabetic mice [Effects of astragalus polysaccharides combined with metformin on glycogen metabolism and ultrastructure in kidney tissue of aging type 2 diabetic mice. Shi Zhen Guo Yi Guo Yao, 2019; 30(4): 827-829; Effect of astragalus polysaccharide combined with metformin on liver glucose and lipid metabolism in aging type 2 diabetes model mice. China Journal of Traditional Chinese Medicine Information, 2019; 26(2): 47-51; Astragalus polysaccharide combined with metformin on Effects and functional analysis of liver mRNA expression profiles in aging diabetic mice. Shi Zhen Guo Yi Guo Yao, 2020; 31(5): 1043-1046]. However, this is an important factor affecting the pharmacological effects of astragalus polysaccharides.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for improving insulin resistance symptoms
  • Pharmaceutical composition for improving insulin resistance symptoms
  • Pharmaceutical composition for improving insulin resistance symptoms

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0060] Example 1: Determination of Astragalus Polysaccharide Molecular Weight

[0061] Weigh 50.0 mg of astragalus polysaccharide sample into a 10 mL volumetric flask, dissolve with 0.1 mol / L sodium nitrate, and dilute to volume. The samples were separated and analyzed using a Waters 1525 high performance liquid chromatograph with an Ultrahydrogel™ Linear chromatographic column, and the analysis time was 30 min. The standards used in the molecular weight calibration curve in the experiment are as follows: Dextran T-300 (Mw300600), Dextran T-150 (Mw 135030), Dextran T-10 (Mw 9750) and Dextran T-5 (Mw 2700). Test results such as figure 1 As shown, there are 4 peaks in the astragalus polysaccharide sample, the retention time (RT) from small to large are Mw 855109 Da (RT = 15.100), Mw 12503 Da (RT = 18.567), Mw 1388 Da (RT 19.220) , Mw 310 Da (RT= 20.470), according to the detection conditions and research literature, it is speculated that the astragalus polysaccharide samples ...

Embodiment 2

[0062] Example 2: Composition of refined astragalus polysaccharide monosaccharide

[0063] Monosaccharide mixed standard preparation: Weigh glucose, mannose, galactose, galactosamine, ribose, arabinose, rhamnose, fucose, glucuronic acid, galacturonic acid, xylose and glucosamine standard Dissolve 72.0 mg of each in a 10 mL volumetric flask, dissolve in ultrapure water, and dilute to volume to prepare a mother solution with a concentration of 7.2 mg / mL for each standard. Take each mother liquor to prepare a mixed monosaccharide standard solution with each monosaccharide concentration of 0.36 mg / mL.

[0064] Derivation of monosaccharide mixed standard solution: Take 100 μL of mixed monosaccharide standard solution and 100 μL of 0.6 mol / L NaOH solution, respectively, and place them in a 1 mL stoppered test tube and mix well. Then take 50 μL of the mixture into a 5 mL stoppered test tube, add 50 μL of 0.5 mol / L 1-phenyl-3-methyl-5-pyrazolone methanol solution, and mix by vortexin...

Embodiment 3

[0068] Example 3: Establishment of a mouse model of insulin resistance

[0069] 40 male C57BL / 6J mice, SPF grade, 6 weeks old (about 20 g, experimental animal license number: SCXK (Beijing) 2019-0009) were purchased from Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd. Breeding conditions: SPF cleanliness, room temperature 20-22ºC, humidity 60 ± 5%, alternating light and dark for 12 hours, free food and water. All animal protocols in this experiment were approved by the Institutional Laboratory Animal Management and Use Committee of Beijing Weitong Lihua Laboratory Animal Technology Co., Ltd., and animal experiments were performed under the guidance of the Laboratory Animal Protection Association.

[0070] Mice were weighed after 1 week of adaptive feeding, and the mice were randomly divided into normal chow diet (NCD) and high-fat diet (HFD) groups according to their body weight. The NCD group (n = 8) was fed with a normal diet, and the HFD group (n = 32) was fed...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Login to View More

Abstract

The invention discloses a pharmaceutical composition for improving insulin resistance symptoms, the pharmaceutical composition is composed of refined astragalus polysaccharide (Mw 12503Da) and metformin, and the refined astragalus polysaccharide is composed of seven monosaccharides including mannose, glucosamine, rhamnose, galacturonic acid, glucose, galactose and arabinose (the content ratio is 0.34: 0.29: 0.14: 0.61: 94.19: 1.17: 3.26). The mass ratio of the refined astragalus polysaccharide to the metformin is (6-9): (2-5), preferably 7: 3. Experiments prove that when the refined astragalus polysaccharide is used for assisting metformin treatment, the hypoglycemic sensitivity of metformin is improved by means of regulating lipid metabolism, enhancing humoral immunity, enhancing cellular immunity, reducing inflammation and the like. According to the application disclosed by the invention, the refined astragalus polysaccharide is found to assist the metformin in treating the insulin resistance disease, no obvious adverse reaction is found, the safety is good, the refined astragalus polysaccharide has the value of being popularized as an effective medicine for assisting in treating the insulin resistance disease, and a new choice is provided for assisting in treating the metformin or assisting in treating the metformin with poor curative effect.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for improving symptoms of insulin resistance. Background technique [0002] Insulin resistance is one of the salient features and an important link in the pathogenesis of type 2 diabetes, and it is also an important risk factor for chronic metabolic syndrome such as cardiovascular disease. It is generally believed that type 2 diabetes is a lifelong disease that is difficult to cure, while insulin resistance is curable. Through early intervention, lifestyle interventions such as strict diet control and increased exercise, insulin resistance can be treated, thereby reducing the conversion rate to type 2 diabetes. [0003] The immune system is the body's first line of defense against microbial, chemical, physical, and psychological damage, repairing damage through a variety of responses, avoiding or isolating threats, and restoring homeostasis. Autoimmunity and chronic inflammation are closel...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/715A61K31/155A61P5/50A61P3/10
CPCA61K31/715A61K31/155A61P5/50A61P3/10A61K2300/00
Inventor 鄢丹龙江兰王爱婷张颖马文娟董琳捷
Owner BEIJING FRIENDSHIP HOSPITAL CAPITAL MEDICAL UNIV